{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T04:46:02Z","timestamp":1772081162126,"version":"3.50.1"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.schres.2023.07.029","type":"journal-article","created":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T09:23:46Z","timestamp":1691054626000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clozapine safety monitoring and related research in psychiatry and neurology in South America: A scoping review"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6839-4614","authenticated-orcid":false,"given":"Trino","family":"Baptista","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5677-3342","authenticated-orcid":false,"given":"Ana","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7760-8987","authenticated-orcid":false,"given":"Alirio Perez Lo","family":"Presti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1737-2233","authenticated-orcid":false,"given":"Alberto","family":"Fernandez-Arana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0156-7511","authenticated-orcid":false,"given":"Helio","family":"Elkis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5910-8575","authenticated-orcid":false,"given":"Mariano","family":"Motuca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3074-7637","authenticated-orcid":false,"given":"Ismael","family":"Olmos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3851-4117","authenticated-orcid":false,"given":"Georgios","family":"Schoretsanitis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2023.07.029_bb0005","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/mds.870080317","article-title":"Modulatory effect of clozapine on levodopa response in Parkinson\u2019s disease: a preliminary study","volume":"8","author":"Arevalo","year":"1993","journal-title":"Mov. Disord."},{"issue":"3\u201316","key":"10.1016\/j.schres.2023.07.029_bb0010","first-page":"19999","article-title":"Obesity induced by antipsychotic drugs: mechanism and management","volume":"100","author":"Baptista","year":"1999","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2023.07.029_bb0015","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1590\/1516-4446-2014-1402","article-title":"A fatal case of ischemic colitis during clozapine administration","volume":"36","author":"Baptista","year":"2014","journal-title":"Rev. Bras. Psiquiatr."},{"key":"10.1016\/j.schres.2023.07.029_bb0020","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1590\/1516-4446-2017-2565","article-title":"Clozapine augmentation helped in a case of obsessive-compulsive disorder complicated with a tardive movement disorder","volume":"40","author":"Baptista","year":"2018","journal-title":"Rev. Bras. Psiquiatr."},{"key":"10.1016\/j.schres.2023.07.029_bb0025","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.schres.2010.10.014","article-title":"The metabolic syndrome and its constituting variables in atypical antipsychotic-treated subjects: comparison with other drug treatments, drug-free psychiatric patients, first-degree relatives and the general population in Venezuela","volume":"126","author":"Baptista","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.07.029_bb0030","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1177\/0004867415585584","article-title":"Heterogeneity of clozapine-associated myocarditis: an opportunity for novel preventing strategies","volume":"49","author":"Baptista","year":"2015","journal-title":"Aust. N Z J. Psychiatry."},{"key":"10.1016\/j.schres.2023.07.029_bb0035","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.schres.2015.05.025","article-title":"Colonic transit diagnostic test shows significant gastrointestinal hypomotility in clozapine-treated patients in comparison with subjects treated with other antipsychotics","volume":"166","author":"Baptista","year":"2015","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.07.029_bb0040","first-page":"352","article-title":"Clozapine-induced myocarditis in observational cross-sectional and follow-up evaluations: comparison with other antipsychotics in naturalistic settings","volume":"57","author":"Baptista","year":"2016","journal-title":"Investig. Clin."},{"key":"10.1016\/j.schres.2023.07.029_bb0045","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/JCP.0000000000000982","article-title":"Clozapine addition following brain surgery in severe primary obsessive-compulsive disorder with tardive movement disorder","volume":"39","author":"Baptista","year":"2019","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2023.07.029_bb0050","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4067\/S0717-95532016000300011","article-title":"Prevalencia de sindromea metab\u00f3lica em pacientes com esquizofrenia refrataria","volume":"22","author":"Batista de Freitas","year":"2016","journal-title":"Cien. Enferm."},{"key":"10.1016\/j.schres.2023.07.029_bb0055","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.schres.2008.03.004","article-title":"Coagulation and inflammation markers during atypical or typical antipsychotic treatment in schizophrenia patients and drug-free first-degree relatives","volume":"103","author":"Carrizo","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.07.029_bb0060","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.schres.2009.05.007","article-title":"Extended-release metformin for metabolic control assistance during prolonged clozapine administration: a 14-week, double-blind, parallel group, placebo-controlled study","volume":"113","author":"Carrizo","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.07.029_bb0065","doi-asserted-by":"crossref","unstructured":"Casta\u00f1eda Ram\u00edrez, J.J., Cardona Deaza, J.L., Miranda Rosero, H., Londo\u00f1o, J.F., 2011. Miocarditis por clozapina: reporte de caso y revisi\u00f3n de tema, Rev. Colomb. Psiquiatr. 40, 170\u2013182. Available from: \u2264http:\/\/www.scielo.org.co\/scielo.php?script=sci_arttext&pid=S0034-74502011000100015&lng=en&nrm=iso> ISSN 0034\u20137450.","DOI":"10.1016\/S0034-7450(14)60113-X"},{"key":"10.1016\/j.schres.2023.07.029_bb0070","first-page":"14","article-title":"759C>T polimorphism of the 5HTR2C gene is associated with second generation antipsychotic-induced weight gain in female patients with schizophrenia","volume":"50","author":"Daray","year":"2017","journal-title":"Pharmacopsychiatr."},{"key":"10.1016\/j.schres.2023.07.029_bb0075","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1590\/S1516-44462005000200020","article-title":"Cardiomiopatia em paciente tratada com clozapina","volume":"27","author":"De Boni","year":"2005","journal-title":"Braz. J. Psychiatry."},{"key":"10.1016\/j.schres.2023.07.029_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.schres.2023.05.004","article-title":"Adverse drug reactions and their fatal outcomes in clozapine patients in VigiBase: comparing the top four reporting countries (US, UK, Canada and Australia)","author":"De las Cuevas","year":"2023","journal-title":"Schizophr. Res. (in press)."},{"key":"10.1016\/j.schres.2023.07.029_bb0085","doi-asserted-by":"crossref","first-page":"411","DOI":"10.24869\/psyd.2022.411","article-title":"Reflections on the complex history of the concept of clozapine-induced inflammation during titration","volume":"34","author":"de Leon","year":"2022","journal-title":"Psychiatr. Danub."},{"key":"10.1016\/j.schres.2023.07.029_bb0090","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1055\/a-1625-6388","article-title":"An international adult guideline for making clozapine titration safer by using 6 ancestry-based personalized dosing titrations, CRP and clozapine levels","volume":"55","author":"de Leon","year":"2022","journal-title":"Pharmacopsychiatry."},{"key":"10.1016\/j.schres.2023.07.029_bb0095","first-page":"363","article-title":"Promoting safer clozapine dosing in the Americas","volume":"44","author":"de Leon","year":"2022","journal-title":"Braz. J. Psychiatry."},{"key":"10.1016\/j.schres.2023.07.029_bb0100","doi-asserted-by":"crossref","DOI":"10.1136\/gpsych-2022-100773","article-title":"An international guideline with six personalised titration schedules for preventing myocarditis and pneumonia associated with clozapine","volume":"35","author":"de Leon","year":"2022","journal-title":"General Psychiatry."},{"key":"10.1016\/j.schres.2023.07.029_bb0105","doi-asserted-by":"crossref","unstructured":"de Leon, J., Arrojo-Romero, M., Verdoux, H., Ruan, Can-Jun, Schoretsanitis, G., Rohde, Ch., Cohen, Dan., Schulte, P.F.J., Kim, Se-Hyun., Cotes, R., Leung, J.G., Otsuka,, Y., Kirilochev, O.O., Baptista, T., Grover, S., Every-Palmer, S., Clark, S.R., McGrane, I.R., Motuca, M., Olmos, I., Wilkowska, A., Sagud, M., Anil Ya\u011fcio\u011flu, A.E., Ristic, D.I., Lazary, J., Sanz, E.J., De Las Cuevas, C., 2023. Escaping the long shadow cast by agranulocytosis: reflections on clozapine pharmacovigilance focused on the United Kingdom. J. Clin. Psychopharmacol. 43, 239\u2013245. doi:https:\/\/doi.org\/10.1097\/JCP.0000000000001678.","DOI":"10.1097\/JCP.0000000000001678"},{"key":"10.1016\/j.schres.2023.07.029_bb0110","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s40263-017-0448-6","article-title":"Clozapine-induced gastrointestinal hypomotility: a 22-year bi-national pharmacovigilance study of serious or fatal \u2018slow gut\u2019 reactions, and comparison with international drug safety advice","volume":"31","author":"Every-Palmer","year":"2017","journal-title":"CNS Drugs."},{"key":"10.1016\/j.schres.2023.07.029_bb0115","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.schres.2010.06.001","article-title":"Polymorphisms of the LEP- and LEPR genes, metabolic profile after prolonged clozapine administration and response to the antidiabetic metformin","volume":"121","author":"Fern\u00e1ndez","year":"2010","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.07.029_bb0120","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.schres.2012.02.005","article-title":"Pro12Ala polymorphism of the PPAR-\u03b32 gene, metabolic syndrome and response to metformin in clozapine-treated patients","volume":"137","author":"Fern\u00e1ndez","year":"2012","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.07.029_bb0125","first-page":"203","article-title":"Clozapine and pancreatitis","volume":"21","author":"Gatto","year":"1998","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.schres.2023.07.029_bb0130","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1590\/1516-4446-2021-1765","article-title":"Risk of neutropenia among clozapine users and non-users: results from 5,847 patients","volume":"44","author":"Goldani","year":"2022","journal-title":"Braz. J. Psychiatry."},{"key":"10.1016\/j.schres.2023.07.029_bb0135","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1590\/S0004-282X2008000500001","article-title":"Use of clozapine in Brazilian patients with Parkinson\u2019s disease","volume":"66","author":"Gomide","year":"2008","journal-title":"Arq. Neuropsiquiatr."},{"key":"10.1016\/j.schres.2023.07.029_bb0140","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2147\/NDT.S37019","article-title":"Weight gain, metabolic disturbances, and physical health care in a Brazilian sample of outpatients with schizophrenia","volume":"9","author":"Gordon","year":"2013","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.schres.2023.07.029_bb0145","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1111\/eip.12777","article-title":"High prevalence of metabolic alterations in Latin American patients at initial stages of psychosis","volume":"13","author":"Iruretagoyena","year":"2019","journal-title":"Early Interv. Psychiatry."},{"key":"10.1016\/j.schres.2023.07.029_bb0150","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1590\/1516-4446-2015-1787","article-title":"Clozapine-induced esophagitis at therapeutic dose: a case report","volume":"38","author":"Javelot","year":"2016","journal-title":"Rev. Bras. Psiquiatr."},{"key":"10.1016\/j.schres.2023.07.029_bb0155","first-page":"231","article-title":"New strategies for old problems: tardive dyskinesia (TD). Review and report on severe TD cases treated with clozapine, with 12, 8 and 5 years of video follow-up","volume":"19","author":"Larach","year":"1997","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.07.029_bb0160","first-page":"120","article-title":"Overweight and obesity in schizophrenic patients taking clozapine compared to the use of other antipsychotics","volume":"28","author":"Leit\u00e3o-Azevedo","year":"2006","journal-title":"Rev. Psiquiatr. RS."},{"key":"10.1016\/j.schres.2023.07.029_bb0165","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1590\/S1516-44462006005000016","article-title":"Increased dyslipidemia in schizophrenic outpatients using new generation antipsychotics","volume":"28","author":"Leit\u00e3o-Azevedo","year":"2006","journal-title":"Braz. J. Psychiatry."},{"key":"10.1016\/j.schres.2023.07.029_bb0170","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/JCP.0000000000001606","article-title":"The modernization of clozapine: a recapitulation of the past in the United States and the view forward","volume":"42","author":"Leung","year":"2022","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2023.07.029_bb0175","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/01.jcp.0000155823.59585.88","article-title":"Maintenance treatment of severe tardive dyskinesia with clozapine: 5 years\u2019 follow-up","volume":"25","author":"Louz\u00e3","year":"2005","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2023.07.029_bb0180","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1590\/S0047-20852006000100011","article-title":"Hepatotoxicidade grave secund\u00e1ria a psicof\u00e1rmacos e indica\u00e7\u00e3o de eletroconvulsoterapia a paciente com esquizofrenia","volume":"55","author":"Maila de Castro","year":"2006","journal-title":"J. Bras. Psiquiatr."},{"key":"10.1016\/j.schres.2023.07.029_bb0185","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/YIC.0b013e328342ce47","article-title":"Abnormal correlation between serum leptin levels and body mass index may predict metabolic dysfunction irrespective of the psychopharmacological treatment","volume":"26","author":"Marquina","year":"2011","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2023.07.029_bb0190","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4067\/S0717-92272004000100005","article-title":"Trastornos metab\u00f3licos en pacientes esquizofr\u00e9nicos tratados con Clozapina","volume":"42","author":"Mu\u00f1oz","year":"2004","journal-title":"Rev. Chil. Neuro-psiquiatr."},{"key":"10.1016\/j.schres.2023.07.029_bb0195","first-page":"101","article-title":"Correlaci\u00f3n de las concentraciones plasm\u00e1ticas de clozapina con el s\u00edndrome metab\u00f3lico","volume":"81","author":"Olmos","year":"2017","journal-title":"Rev. Psiquiatr. Urug."},{"key":"10.1016\/j.schres.2023.07.029_bb0200","first-page":"3163502","article-title":"Population pharmacokinetics of clozapine and norclozapine and switchability assessment between brands in Uruguayan patients with schizophrenia","volume":"19","author":"Olmos","year":"2019","journal-title":"Biomed. Res. Int."},{"issue":"e83","key":"10.1016\/j.schres.2023.07.029_bb0205","first-page":"1","article-title":"Clozapine haematological monitoring for neutropenia: a global perspective","volume":"31","author":"Oloyede","year":"2022","journal-title":"Epidemiol. Psychiatr. Sci."},{"key":"10.1016\/j.schres.2023.07.029_bb0210","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.schres.2008.08.031","article-title":"Frequency of abnormal correlation between leptin and the body mass index during first and second generation antipsychotic drug treatment","volume":"106","author":"Pe\u00f1a","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.07.029_bb0215","first-page":"399","article-title":"Toma de decisiones en un paciente con pericarditis asociada a clozapina y c\u00e1ncer avanzado","volume":"30","author":"Picco","year":"2019","journal-title":"Vertex Rev. Argent. Psiquiatr."},{"key":"10.1016\/j.schres.2023.07.029_bb0220","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1590\/1518-8345.2222.2983","article-title":"Prevalence of polymorphisms in the ANKK1, DRD2, DRD3 genes and metabolic syndrome in refractory schizophrenia","volume":"26","author":"Pinto","year":"2018","journal-title":"Rev. Lat. Am Enfermagem."},{"key":"10.1016\/j.schres.2023.07.029_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajp.2022.103192","article-title":"Metabolic syndrome and cardiovascular risk between clozapine and non-clozapine antipsychotic users with schizophrenia","volume":"74","author":"Quek","year":"2022","journal-title":"Asian J. Psychiatr."},{"key":"10.1016\/j.schres.2023.07.029_bb0230","doi-asserted-by":"crossref","DOI":"10.1111\/bcp.15691","article-title":"A population pharmacokinetic model to guide clozapine dose selection, based on age, sex, ethnicity, body weight and smoking status","author":"Reeves","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.schres.2023.07.029_bb0235","doi-asserted-by":"crossref","first-page":"216","DOI":"10.20453\/rnp.v79i4.2976","article-title":"Perfil metab\u00f3lico y factores asociados en pacientes con esquizofrenia bajo tratamiento con antipsic\u00f3ticos que acuden a consulta externa en el Instituto Nacional de Salud Mental (Per\u00fa)","volume":"79","author":"Ricapa","year":"2016","journal-title":"Rev. Neuropsiquiatr."},{"key":"10.1016\/j.schres.2023.07.029_bb0240","first-page":"1417","article-title":"Risk of type 2 diabetes mellitus among users of atypical antipsychotic drugs or conventional treatment: systematic review and meta-analysis","volume":"137","author":"Sapunar","year":"2010","journal-title":"Rev. Med. Chil."},{"key":"10.1016\/j.schres.2023.07.029_bb0245","doi-asserted-by":"crossref","unstructured":"Schoretsanitis, G., Smith, R.L, Molden, E., Solismaa, A., Sepp\u00e4l\u00e4, N., Kope\u010dek, M., \u0160vancer, P., Olmos, I., V\u00e1zquez, M., Iglesias-Garcia, C., Iglesias-Alonso, A., Spina, E., de Leon, J., 2021. European whites may need lower minimum therapeutic clozapine doses than those customarily proposed. J. Clin. Psychopharmacol. 41, 140\u2013147. doi:https:\/\/doi.org\/10.1097\/JCP.0000000000001341.","DOI":"10.1097\/JCP.0000000000001341"},{"key":"10.1016\/j.schres.2023.07.029_bb0250","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1590\/S0004-27302007000300019","article-title":"Diabetes mellitus associado com drogas antipsic\u00f3ticas at\u00edpicas: relato de caso e revis\u00e3o da literatura","volume":"51","author":"Sep\u00falveda Reis","year":"2007","journal-title":"Arq. Bras. Endocrinol. Metab."},{"key":"10.1016\/j.schres.2023.07.029_bb0255","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1177\/0004867413502089","article-title":"Safety of long-term clozapine administration. Frequency of cardiomyopathy and hyponatraemia: two cross-sectional, naturalistic studies","volume":"48","author":"Serrano","year":"2014","journal-title":"Aust. N Z J. Psychiatry."},{"key":"10.1016\/j.schres.2023.07.029_bb0260","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1590\/S1516-44462007000400007","article-title":"The prevalence of metabolic syndrome among psychiatric inpatients in Brazil","volume":"29","author":"Teixeira","year":"2007","journal-title":"Braz. J. Psychiatry."},{"key":"10.1016\/j.schres.2023.07.029_bb0265","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S2215-0366(22)00044-X","article-title":"Long-term treatment with clozapine and other antipsychotic drugs and the risk of haematological malignancies in people with schizophrenia: a nationwide case-control and cohort study in Finland","volume":"9","author":"Tiihonen","year":"2022","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.schres.2023.07.029_bb0270","doi-asserted-by":"crossref","first-page":"5361","DOI":"10.2217\/nmt-2021-0021","article-title":"Potentially inappropriate prescriptions of antipsychotic and anticholinergic drugs in patients with Parkinson\u2019s disease","volume":"11","author":"Valladales-Restrepo","year":"2021","journal-title":"Neurodegener. Dis. Manag"},{"key":"10.1016\/j.schres.2023.07.029_bb0275","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/pnp.750","article-title":"Use of clozapine for psychosis and chorea in Huntington's disease systematic narrative review","volume":"26","author":"Wildridge","year":"2022","journal-title":"Prog. Neurol. Psychiatry"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996423002554?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996423002554?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T09:50:32Z","timestamp":1691142632000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996423002554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":55,"alternative-id":["S0920996423002554"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2023.07.029","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clozapine safety monitoring and related research in psychiatry and neurology in South America: A scoping review","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2023.07.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}